On March Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing platform, reported that it will present preclinical data for OTX-2002, the Company’s lead drug candidate for the treatment of hepatocellular carcinoma (HCC), at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, taking place in New Orleans, Louisiana, April 8-13, 2022 (Press release, Omega Therapeutics, MAR 8, 2022, View Source [SID1234609722]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"These preclinical data highlight the potential of epigenetic modulation of the c-MYC (MYC) oncogene as a promising new approach for the treatment of hepatocellular carcinoma (HCC), where MYC over expression is associated with aggressive disease in up to 70% of HCC cases," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "While MYC represents an attractive therapeutic target, it has historically been considered undruggable, due to the consistent failure of current modalities to inhibit MYC directly or indirectly. We look forward to sharing these data that support the potential of epigenetic modulation using our platform to systematically control the underlying biology of gene expression and remain on track to file an Investigational New Drug application for OTX-2002 in the first half of 2022."
Details for the AACR (Free AACR Whitepaper) Annual Meeting 2022 poster presentation are as follows:
Title: Epigenetic modulation of the MYC oncogene as a potential novel therapy for HCC
Abstract #: 2629
Date and Time: Tuesday, April 12, 2022 at 9:00 a.m. through 12:30 p.m. CDT
The poster will be posted to our website at View Source at the same time as the presentation.
About OTX-2002
OTX-2002 is a first-in-class Omega Epigenomic Controller in development for the treatment of hepatocellular carcinoma (HCC). OTX-2002 is designed to modulate levels of c-MYC (MYC) expression by utilizing targeted mRNA-encoded proteins to mediate epigenetic regulation while potentially overcoming MYC auto regulation. The MYC oncogene is associated with aggressive disease in up to ~70% of patients with HCC. Omega is currently evaluating OTX-2002 in Investigational New Drug (IND)-enabling studies.